Bizarre Patents
A fork with timer for providing a cue to a user after an elapsed period of time for indicating that another bite of food using the fork may be taken.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183346 | Anti-ferroportin 1 monoclonal antibodies and uses thereof Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the leve... | 05/22/2012 |
| 8153125 | CD20 binding molecules The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human... | 04/10/2012 |
| 8128927 | Methods of using TGF-β 1 binding compositions TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided. ... | 03/06/2012 |
| 7927593 | TGF-beta binding antibodies The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal. ... | 04/19/2011 |
| 7820163 | Anti-hepcidin antibodies and uses thereof Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for in... | 10/26/2010 |
| 7740847 | Variant Fc regions The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating... | 06/22/2010 |
| 7723484 | Anti-EGFR antibodies The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR m... | 05/25/2010 |
| 7619069 | Antibodies to TGF-beta 1 TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided. ... | 11/17/2009 |
| 7226758 | Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF) A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A ge... | 06/05/2007 |
| 7138251 | Polynucleotides encoding a neurotrophic factor receptor The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention ... | 11/21/2006 |
| 6919426 | Peptides and related molecules that modulate nerve growth factor activity The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically ac... | 07/19/2005 |
| 6723701 | Protein analogs of brain-derived neurotrophic factor The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charg... | 04/20/2004 |
